Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer

Phase II Evaluation of Gleevec Combined With Camptosar Plus Paraplatin in Patients With Previously Untreated Extensive Stage SCLC

This study will evaluate combination chemotherapy for patients with extensive stage small cell lung cancer combined with the potentially useful growth inhibiting effects of Gleevec.

Upon determination of eligibility, all patients will be receive:

• Irinotecan + Carboplatin + Imatinib

Inclusion Criteria:

To be included in this study, you must meet the following criteria:

• Small cell lung cancer with extensive stage disease confirmed by biopsy
• Measurable or evaluable disease
• Ability to perform activities of daily living with minimal assistance
• Adequate bone marrow, liver and kidney
• No active brain metastasis.
• No previous chemotherapy or radiation therapy
• Give written informed consent.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

• Limited stage disease (includes IA, IB, IIA, IIB, and IIIA)
• Active brain metastasis
• Age < 18 years old
• History of a prior malignancy within three years
• Women pregnant or lactating.

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.